Recursion Pharmaceuticals (RXRX) Competitors

Recursion Pharmaceuticals (NASDAQ:RXRX) and Roivant Sciences (NASDAQ:ROIV) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Which has more risk and volatility, RXRX or ROIV?

Recursion Pharmaceuticals has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, Roivant Sciences has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500.

Is RXRX or ROIV more profitable?

Recursion Pharmaceuticals has a net margin of -1,004.91% compared to Roivant Sciences' net margin of -2,111.79%. Roivant Sciences' return on equity of -15.90% beat Recursion Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Recursion Pharmaceuticals	-1,004.91%	-76.09%	-54.29%
Roivant Sciences	-2,111.79%	-15.90%	-14.95%

Do institutionals and insiders believe in RXRX or ROIV?

89.1% of Recursion Pharmaceuticals shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 8.4% of Recursion Pharmaceuticals shares are held by insiders. Comparatively, 10.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Do analysts prefer RXRX or ROIV?

Recursion Pharmaceuticals currently has a consensus target price of $7.00, suggesting a potential upside of 44.03%. Roivant Sciences has a consensus target price of $16.50, suggesting a potential upside of 38.19%. Given Recursion Pharmaceuticals' higher probable upside, equities research analysts plainly believe Recursion Pharmaceuticals is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Recursion Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Roivant Sciences	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	3.25

Does the media favor RXRX or ROIV?

In the previous week, Recursion Pharmaceuticals had 3 more articles in the media than Roivant Sciences. MarketBeat recorded 11 mentions for Recursion Pharmaceuticals and 8 mentions for Roivant Sciences. Roivant Sciences' average media sentiment score of 1.08 beat Recursion Pharmaceuticals' score of 0.87 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Recursion Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Roivant Sciences	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher earnings and valuation, RXRX or ROIV?

Roivant Sciences has lower revenue, but higher earnings than Recursion Pharmaceuticals. Roivant Sciences is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Recursion Pharmaceuticals	$58.84M	35.86	-$463.66M	-$1.78	-2.73
Roivant Sciences	$29.05M	280.67	-$171.98M	-$0.70	-17.06

Summary

Roivant Sciences beats Recursion Pharmaceuticals on 10 of the 17 factors compared between the two stocks.